IPO Outlook For The Week: Biotechs And A Grocery Outlet

The IPO dates below are expected but not confirmed.

Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between $14 and $16 Wednesday on the Nasdaq. The offering represents 22.1% of outstanding shares and is expected to raise $123.3 million. Based in Massachusetts, the biotech company develops therapies for genetic conditions of the eye, liver, kidney and central nervous system.

Akero Therapeutics, Inc. (AKRO) will issue 5 million shares between $14 and $16 Thursday on the Nasdaq. The offering represents 19% of outstanding shares and is expected to raise $92 million. Headquartered in San Francisco, Akero is advancing its primary therapy for non-alcoholic steatohepatitis.

Atreca, Inc. (BCEL) will issue 7.35 million shares between $16 and $18 Thursday on the Nasdaq. The offering represents 32.2% of outstanding shares and is expected to raise $152.1 million. The California biotech company develops antibody-based oncological therapies with its proprietary Discovery Platform.

Dermavant Sciences Ltd (DRMT) will issue 7.7 million shares between $12 and $14 Thursday on the Nasdaq. The offering represents 31.4% of outstanding shares and is expected to raise $124 million. The Roivant Sciences subsidiary is advancing five candidates for various dermatological conditions.

Grocery Outlet Holding Corp. (GO) will issue about 17.2 million shares between $15 and $17 Thursday on the Nasdaq. The offering represents 20.1% of outstanding shares and is expected to raise $336 million. The 73-year-old company operates more than 300 grocery stores in the U.S.

Personalis, Inc. (PSNL) will issue nearly 6.7 million shares between $14 and $16 Thursday on the Nasdaq. The offering represents 23.4% of outstanding shares and is expected to raise $122.7 million. Founded in 2011 by a team of Stanford University scientists, Personalis uses genome sequencing and analytics to develop cancer vaccines and immunotherapies.

Prevail Therapeutics Inc. (PRVL) will issue nearly 7.4 million shares between $16 and $18 Thursday on the Nasdaq. The offering represents 21.6% of outstanding shares and is expected to raise $152.2 million. Since 2017, the New York biotech company has been targeting neurodegenerative diseases such as lysosomal dysfunction and Parkinson’s.

1 2
View single page >> |

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.